Results 111 to 120 of about 9,231 (199)

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials

eJHaem
Introduction Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life.
Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik   +11 more
doaj   +1 more source

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor

, 2017
Palma Manduzio Department of Haematology and Oncology, Haematology With BMT, IRCCS, Casa Sollievo della Sofferenza, Foggia, Italy Abstract: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm classified according to the 2016 revision of World ...
Manduzio P
core  

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY‐1 and MOMENTUM Trials

European Journal of Haematology, Volume 117, Issue 5, Page 1265-1274, November 2026.
In this post hoc analysis of the phase 3 SIMPLIFY‐1 and MOMENTUM trials, the number of patients with baseline hemoglobin < 10 g/dL who achieved hemoglobin ≥ 10 g/dL by week 24 with momelotinib, as well as the time to achievement, were evaluated. Patients who were JAK inhibitor naive and/or had moderate anemia were more likely and faster to achieve this
Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal P. McLornan, Steffen Koschmieder, Juan Carlos Hernandez‐Boluda, Kazuya Shimoda, Shiyuan Zhang, Catherine Ellis, Jessica Lim, Jasmine Sahni, Vikas Gupta   +11 more
wiley   +1 more source

Acute massive myelofibrosis with acutelymphoblastic leukemia

Turkish Journal of Hematology, 2009
Acute myelofibrosis is characterized by pancytopenia of sudden onset, megakaryocytic hyperplasia, extensive bone marrow fibrosis, and the absence of organomegaly. Acute myelofibrosis in patients with acute lymphoblastic leukemia is extremely rare.
Namık Özbek, Bülent Celasun, Feride Iffet Şahin, Meltem Gülşan, Barış Malbora, Zekai Avcı   +5 more
doaj  

Practical management of myelofibrosis with ruxolitinib

, 2015
Treatment for the majority of patients with myelofibrosis is primarily based on symptom control as curative allogeneic stem cell transplantation is typically offered only to younger patients, especially those with poor prognosis disease.
Marlton, P., Ritchie, D, Stevenson, W., Dunlop, L.C., Ritchie, D., Ross, David M., Durrant, S, Ho, PJ, Tam, C., Bird, R, Ho, Joy, Ross, DM, Ross, D.M., Marlton, Paula V., Stevenson, W, Dunlop, LC, Ritchie, David, Dunlop, Lindsay C. (R18423), Tam, Constantine, Tam, C, Bird, R., Ho, P.J., Marlton, P, Bird, Robert J., Durrant, S., Durrant, Simon   +25 more
core   +1 more source

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

Arthritis Care &Research, Volume 78, Issue 10, Page 1449-1466, October 2026.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci, Megan R. W. Barber, Ann E. Clarke, Sindhu R. Johnson, Anselm Mak, Hermine I. Brunner, Murat Inanc, Rosalind Ramsey‐Goldman, Guillermo Ruiz‐Irastorza, Ellen M. Ginzler, John G. Hanly, Alexandra Legge, Cynthia Aranow, Laurent Arnaud, Nathalie Costedoat‐Chalumeau, Dafna D. Gladman, Søren Jacobsen, Michelle Petri, Clovis A. Silva, Évelyne Vinet, Alexandre E. Voskuyl, SDI Revision Literature Review Groups, SDI Revision Delphi Panel, SDI Revision Item Reduction Committee, SDI Revision Clinical Domain Groups, Ian N. Bruce   +25 more
wiley   +1 more source

CO‐Rebreathing in Essential Thrombocythemia and Polycythemia Vera. A Revival of an Old Methodology to Improve Diagnosis and Phlebotomy Decisions

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT The diagnostic landscape for the Philadelphia‐negative myeloproliferative neoplasms (MPNs), particularly in distinguishing Essential Thrombocythemia (ET) from Polycythemia Vera (PV), is compromised. The gold standard for diagnosing PV—measurement of red cell mass (RCM) by radioisotope dilution—has been largely abandoned, leading to widespread ...
Hans C. Hasselbalch, Morten Kranker Larsen, Lea Løffler, Camilla Andersen, Isabella Davidsen, Mette Grymer Jensen, Jonas Bechlund, Lasse Kjær, Vibe Skov, Henning Bay Nielsen, Carsten Lundby   +10 more
wiley   +1 more source

Diffuse osteolytic lesions in leukemic transformation of myelofibrosis

, 2014
Myelofibrosis is a clonal myeloproliferative disorder characterized by splenomegaly, abnormal deposition of reticulin and collagen in the bone marrow, extramedullary hematopoiesis, dacryocytosis and leukoerythroblastic blood smear.
Nataša Čolović, Vladimir Jurišić, Milica Čolović, Sonja Pavlović   +3 more
core  

Primary Myelofibrosis - 5

, 2018
An image from a peripheral blood smear showing tears, elliptocytes, schistocytes, and a giant platelet seen in patients with primary myelofibrosis (50X oil immersion).
To, Michelle, Kwon, Gloria
core   +1 more source

Extensive Cerebral Venous Sinus Thrombosis With Obstructive Hydrocephalus in a Young Female With Underlying Essential Thrombocythemia: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Persistent symptoms suggestive of idiopathic intracranial hypertension despite standard therapy should prompt urgent neuroimaging to exclude cerebral venous sinus thrombosis. When CVST is confirmed without an obvious provoking factor, evaluation for underlying myeloproliferative neoplasms, including JAK2‐positive essential thrombocythemia, is ...
Sarah Nafea, Tasmia Farooq, Md Abu Taher, Andrea Barros, Kyaw Naing Soe, Fawad Ali, Koshy Thomas   +6 more
wiley   +1 more source